Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:81282 |
Name | oligodendroglioma, IDH-mutant and 1p/19q-codeleted, grade 3 |
Definition | An IDH-mutant, and 1p/19q-codeleted oligodendroglioma that is characterized as grade 3 tumors associated with a more rapid growth. Grade 3 tumors appear to have abnormalities on chromosomes 9 or 10, along with unusual amounts of growth factors and proteins, which are thought to contribute to the more rapid growth of these gliomas. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer cell type cancer high grade glioma oligodendroglioma anaplastic oligodendroglioma IDH-mutant and 1p/19q-codeleted oligodendroglioma oligodendroglioma, IDH-mutant and 1p/19q-codeleted, grade 3 |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05804227 | Phase I | Ulixertinib | Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Low-Grade Gliomas in Adults | Recruiting | USA | 0 |
NCT06478212 | Phase Ib/II | Temozolomide + Vorasidenib | Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma | Not yet recruiting | USA | NLD | ITA | ISR | GBR | FRA | ESP | DEU | AUT | 2 |